X

Trial Profile

A phase 3 study of pegcetacoplan in patients with C3G or IC-MPGN

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 11 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pegcetacoplan (Primary)
Indications Glomerulonephritis; Membranoproliferative glomerulonephritis
Focus Registrational; Therapeutic Use
Sponsors Apellis Pharmaceuticals

Most Recent Events

04 May 2022 According to an Apellis Pharmaceuticals media release, the company expects to initiate this study in the second quarter of 2022.
09 Aug 2021 According to an Apellis Pharmaceuticals media release, In the second half of 2021, Apellis expects to initiate a Phase 3 study in immune complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G).
05 Nov 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com